Trial Profile
A Bioequivalence and Food Effect Study in Healthy Subjects Administered 2 Different Tablet Formulations of LY3314814
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 04 Apr 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Feb 2016 New trial record